# Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma

> **NCT00538733** · PHASE2 · COMPLETED · sponsor: **Weill Medical College of Cornell University** · enrollment: 26 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** thalomid
- **DRUG:** lenalidomide
- **DRUG:** clarithromycin
- **DRUG:** dexamethasone

## Key facts

- **NCT ID:** NCT00538733
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2010-07
- **Final completion:** 2020-09-17
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2021-05-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00538733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00538733, "Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00538733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*